Autolus Therapeutics (NASDAQ:AUTL) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• Autolus Therapeutics has been upgraded to a "hold" rating by Wall Street Zen, shifting from a previous "sell" rating.
• Wells Fargo lowered its price target for Autolus Therapeutics from $6.00 to $5.00, while Needham & Company maintained a "buy" rating with a target of $10.00.
• The company reported earnings of ($0.18) per share for the last quarter, outperforming the consensus estimate of ($0.24), with revenues reaching $13.50 million.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also recently issued reports about the company. Wells Fargo & Company reduced their price target on Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, July 21st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $9.12.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $1.78 on Friday. The firm has a market cap of $473.73 million, a PE ratio of -2.12 and a beta of 1.90. The stock's fifty day moving average price is $2.32 and its two-hundred day moving average price is $1.89. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.06. The company had revenue of $13.50 million during the quarter, compared to analysts' expectations of $12.92 million. Sell-side analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AUTL. Jane Street Group LLC purchased a new position in Autolus Therapeutics during the fourth quarter worth about $26,000. Barclays PLC grew its position in Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after buying an additional 10,866 shares in the last quarter. R Squared Ltd purchased a new position in Autolus Therapeutics during the second quarter worth about $50,000. Invesco Ltd. grew its position in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after buying an additional 11,381 shares in the last quarter. Finally, Delaney Dennis R purchased a new position in Autolus Therapeutics during the second quarter worth about $55,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.